[TABLE OF CONTENTS] 

1 INTRODUCTION OF GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 INSTRUMENT
5.3 REAGENTS
5.4 OTHER

6 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY TYPE
6.1 OVERVIEW
6.2 POLYMERASE CHAIN REACTION (PCR)
6.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
6.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
6.5 IN-SITU HYBRIDIZATION
6.6 MASS SPECTROMETRY
6.7 TRANSCRIPTION MEDIATED AMPLIFICATION (TMA)
6.8 CHIPS AND MICROARRAYS
6.9 OTHER TECHNOLOGY TYPES

7 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION TYPE
7.1 OVERVIEW
7.2 BREAST CANCER
7.3 PROSTATE CANCER
7.4 COLORECTAL CANCER
7.5 LUNG CANCER
7.6 BLOOD CANCER
7.7 LIVER CANCER
7.8 CERVICAL CANCER
7.9 OTHER APPLICATION TYPES

8 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END-USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 DIAGNOSTIC CENTERS
8.4 OTHERS

9 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY
9.1 OVERVIEW

9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO

9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3. 1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE

9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC

9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA

9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA

10 GLOBAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES

11 COMPANY PROFILES

11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS

11.2 F. HOFFMANN LA-ROCHE LIMITED
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS

11.3 DANAHER CORPORATION (CEPHEID)
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS

11.4 SYSMEX CORPORATION (SYSMEX EUROPE GMBH)
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS

11.5 ILLUMINA, INCORPORATED
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS

11.6 THERMO FISHER SCIENTIFIC INCORPORATED
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS

11.7 BIOMÉRIEUX SA
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS

11.8 VERACYTE INCORPORATED
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS

11.9 AGILIENT TECHNOLOGIES INCORPORATED
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS

11.10 TBG DIAGNOSTICS LIMITED
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS

11.11 HTG MOLECULAR DIAGNOSTICS INCORPORATED
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS

11.12 QIAGEN
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS